These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17211098)

  • 1. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2008 Jan; 18(1):20-6. PubMed ID: 18175867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical application of calcimimetics].
    Nishi H; Fukagawa M
    Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].
    Kebig A; Mohr K
    Dtsch Med Wochenschr; 2008 Aug; 133(33):1681-3. PubMed ID: 18661462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Parathyroid and bone. Calcimimetics and bone metabolism].
    Fukumoto S
    Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet hydrochloride.
    Barman Balfour JA; Scott LJ
    Drugs; 2005; 65(2):271-81. PubMed ID: 15631545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
    Franceschini N; Joy MS; Kshirsagar A
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1413-21. PubMed ID: 12882626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet.
    Apostolou T; Damianou L; Kotsiev V; Drakopoulos S; Hadjiconstantinou V
    Clin Nephrol; 2006 May; 65(5):374-7. PubMed ID: 16724661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Insight: renal indications of calcimimetics.
    Shahapuni I; Monge M; Oprisiu R; Mazouz H; Westeel PF; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):316-25. PubMed ID: 16932453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.